Trupti Upadhye Bannore Selected Research

Nausea

1/2021

Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, 90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Trupti Upadhye Bannore Research Topics

Disease

2	Neoplasms (Cancer) 06/2023 - 12/2022
1	Fibrosarcoma 12/2022
1	Abdominal Pain (Pain, Abdominal) 01/2021
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2021
1	Nausea 01/2021

Drug/Important Bio-Agent (IBA)

2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 06/2023 - 12/2022
1	IntegrinsIBA 06/2023
1	D-Aspartic Acid (D Aspartate)IBA 06/2023
1	AcidsIBA 06/2023
1	Arginine (L-Arginine)FDA Link 06/2023
1	RadiopharmaceuticalsIBA 06/2023
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 06/2023
1	PAMAM StarburstIBA 12/2022
1	PorphyrinsIBA 12/2022
1	lutetium Lu 177 dotatateIBA 01/2021
1	Radioisotopes (Radionuclides)IBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2021
1	Peptide Receptors (Peptide Receptor)IBA 01/2021
1	DOTA(0)-Tyr(3)-Thr(8)- 90Y-octreotateIBA 01/2021

Therapy/Procedure

1	Therapeutics 01/2021